Forte Biosciences shares are trading higher after the company announced results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!